Articles

Rechallenge with Immune Checkpoint Inhibitors in Patients with Lung Cancer Associated with More Severe Interstitial Lung Disease

Patients with KRAS G12C non–small-cell lung cancer appear to have improved progression-free survival before immunotherapy than patients with non-KRAS G12C lung cancer, but there was no improvement in overall survival between the 2 groups. Read More ›

More severe interstitial lung disease with more severe radiological features was found on second occurrence in patients with lung cancer who were rechallenged with ICI treatment. Read More ›

Accumulating Adverse Events May Cause Patients with Multiple Myeloma to Be Reluctant to Adhere to Their Treatment Plan

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss how they use shared decision-making with patients to help them remain adherent to their treatment plan. Read More ›

Who Are the Patients with Multiple Myeloma Who May Not Adhere to Their Treatment Regimen?

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, talk about the clues and the patient characteristics that they use to determine which of their patients with multiple myeloma may be at risk for not adhering to their anticancer therapy. Read More ›

Best Practices for Keeping Patients with Multiple Myeloma Adherent to Therapy

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Patients with multiple myeloma often face a difficult road in their cancer journey because of their treatment regimen. Please join Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, as they share some of their best practices for keeping patients on therapy. Read More ›

Patients with Multiple Myeloma Harbor Misconceptions About Treatment Adherence

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, break down the misconceptions that patients with multiple myeloma may have about the different treatment regimens and how those misconceptions can affect their views on treatment adherence. Read More ›

By Jonathan Wesley Riess, MD, MS

NSCLC

Supplements

Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Read More ›

Liquid Biopsy in Advanced NSCLC Expedites Tumor Screening and Treatment Initiation

Nephrotoxicity Risk Factors with Use of Pemetrexed in Patients with NSCLC

Liquid biopsy improves turnaround time for molecular genotyping, but further improvement in next-generation sequencing is recommended. Read More ›